Answer the following “cause-effect” true/false questions using the answer key: A: Only statement A is true. B: Only statement B is true. C: Both statements A and B are true, but B is not the exclusive cause of A.. D: Both statements A and B are true, and B is the exclusive cause of A. E: Neither statement A nor B is true. Question 12: A. Cerebral amyloid angiopathy is often found in cases of AD with parenchymal amyloid beta deposits because B. Lewy bodies are common in the setting of low AD neuropathologic changes causing significant vascular brain injury. Question 13: A. Diabetes, mid-life hypertension, mid-life obesity, and physical inactivity are risk factors for AD because B. The clinical and behavioral symptoms of cerebrovascular disease can be similar to that of AD.
Question 14: A. Reduced metabolism of amyloid-beta-42 is a current hypothesis of disease progression in older adults because B. Inhibition or dysfunction of clearance mechanisms for amyloid-beta-42 from the extracellular space promotes accumulation of neuritic plaques and neurofibrillary tangles in neurons.
Answer the following “cause-effect” true/false questions using the answer key: A: Only statement A is true. B: Only statement B is true. C: Both statements A and B are true, but B is not the exclusive cause of A.. D: Both statements A and B are true, and B is the exclusive cause of A. E: Neither statement A nor B is true. Question 12: A. Cerebral amyloid angiopathy is often found in cases of AD with parenchymal amyloid beta deposits because B. Lewy bodies are common in the setting of low AD neuropathologic changes causing significant vascular brain injury. Question 13: A. Diabetes, mid-life hypertension, mid-life obesity, and physical inactivity are risk factors for AD because B. The clinical and behavioral symptoms of cerebrovascular disease can be similar to that of AD. Question 14: A. Reduced metabolism of amyloid-beta-42 is a current hypothesis of disease progression in older adults because B. Inhibition or dysfunction of clearance mechanisms for amyloid-beta-42 from the extracellular space promotes accumulation of neuritic plaques and neurofibrillary tangles in neurons.
Human Anatomy & Physiology (11th Edition)
11th Edition
ISBN:9780134580999
Author:Elaine N. Marieb, Katja N. Hoehn
Publisher:Elaine N. Marieb, Katja N. Hoehn
Chapter1: The Human Body: An Orientation
Section: Chapter Questions
Problem 1RQ: The correct sequence of levels forming the structural hierarchy is A. (a) organ, organ system,...
Related questions
Question
Answer the following “cause-effect” true/false questions using the answer key:
A: Only statement A is true.
B: Only statement B is true.
C: Both statements A and B are true, but B is not the exclusive cause of A..
D: Both statements A and B are true, and B is the exclusive cause of A.
E: Neither statement A nor B is true.
Question 12:
A. Cerebral amyloid angiopathy is often found in cases of AD with parenchymal amyloid beta deposits because
B. Lewy bodies are common in the setting of low AD neuropathologic changes causing significant vascular brain injury.
Question 13:
A. Diabetes, mid-life hypertension, mid-life obesity, and physical inactivity are risk factors for AD because
B. The clinical and behavioral symptoms of cerebrovascular disease can be similar to that of AD.
Question 14:
A. Reduced metabolism of amyloid-beta-42 is a current hypothesis of disease progression in older adults because
B. Inhibition or dysfunction of clearance mechanisms for amyloid-beta-42 from the extracellular space promotes accumulation of neuritic plaques and neurofibrillary tangles in neurons.
Question 15:
A. Amyloid-beta-42 is thought to be a pathogenic peptide involved in AD in part because
B. Most mutations in APP, PSEN1 and PSEN2 are associated with an overproduction of amyloid-beta-42.
Question 16:
A. Destabilization of cytoskeletal elements by hyperphosphorylation can contribute to the pathogenesis of AD because
B. The microtubule-associated protein Tau aids in microtubule assembly and stabilization.
Question 17:
A. Amyloid-beta that is released from neurons into the extracellular space is non-toxic because
B. Diffusible amyloid-beta cannot aggregate to form plaques that damage adjacent synapses.
Question 18:
A. Tau levels are measurable in the CSF of all individuals, including healthy individuals and those with AD because
B. The AD CSF profile refers to the combination of low CSF amyloid beta-42 and high T-tau and P-tau levels, and is used as a diagnostic measure due to its high sensitivity.
Question 19:
A. The definitive diagnosis of AD is made based on changes in memory, cognition, and function because
B. In the pre-symptomatic period of dominantly inherited AD, there is a decline in CSF levels of amyloid-beta 42.
Question 20:
A. Donepezil is a cognition-enhancing drug approved for use in AD because
B. Donepezil reduces the effect of acetylcholine on postsynaptic nicotinic receptors.
Question 21:
A. Cerebrovascular disease has been associated with worse cognitive performance in patients with AD because
B. Decreased blood flow before beta amyloid deposition contributes directly to amyloid accumulation due to the reduced clearance of amyloid.
Question 22:
A. Amyloid-beta deposits occur in the walls of blood vessels in the brain of AD patients because
B. Diffusible amyloid-beta oligomers are taken up by astrocytes and endothelial cells via low-density lipoprotein receptor-related protein 1.
Question 23:
A. Pathological forms of tau may account for the spread of AD in the brain because
B. Hyperphosphorylation of tau protein leads to transmission of pathologic forms of tau between neurons.
Expert Solution
Step 1: Introduction
The questions inquired are related to the cause-effect relationship between two statements, each relating to a particular viewpoint of Alzheimer’s Disease (AD). They investigate different aspects of AD. These questions require an understanding of both explanations and their interrelation to decide whether one is the select cause of the other, both are independently true, or neither is true.
As per our policy, we can only answer the first 3 questions. Kindly repost for the other questions.
Step by step
Solved in 3 steps
Knowledge Booster
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, biology and related others by exploring similar questions and additional content below.Recommended textbooks for you
Human Anatomy & Physiology (11th Edition)
Biology
ISBN:
9780134580999
Author:
Elaine N. Marieb, Katja N. Hoehn
Publisher:
PEARSON
Biology 2e
Biology
ISBN:
9781947172517
Author:
Matthew Douglas, Jung Choi, Mary Ann Clark
Publisher:
OpenStax
Anatomy & Physiology
Biology
ISBN:
9781259398629
Author:
McKinley, Michael P., O'loughlin, Valerie Dean, Bidle, Theresa Stouter
Publisher:
Mcgraw Hill Education,
Human Anatomy & Physiology (11th Edition)
Biology
ISBN:
9780134580999
Author:
Elaine N. Marieb, Katja N. Hoehn
Publisher:
PEARSON
Biology 2e
Biology
ISBN:
9781947172517
Author:
Matthew Douglas, Jung Choi, Mary Ann Clark
Publisher:
OpenStax
Anatomy & Physiology
Biology
ISBN:
9781259398629
Author:
McKinley, Michael P., O'loughlin, Valerie Dean, Bidle, Theresa Stouter
Publisher:
Mcgraw Hill Education,
Molecular Biology of the Cell (Sixth Edition)
Biology
ISBN:
9780815344322
Author:
Bruce Alberts, Alexander D. Johnson, Julian Lewis, David Morgan, Martin Raff, Keith Roberts, Peter Walter
Publisher:
W. W. Norton & Company
Laboratory Manual For Human Anatomy & Physiology
Biology
ISBN:
9781260159363
Author:
Martin, Terry R., Prentice-craver, Cynthia
Publisher:
McGraw-Hill Publishing Co.
Inquiry Into Life (16th Edition)
Biology
ISBN:
9781260231700
Author:
Sylvia S. Mader, Michael Windelspecht
Publisher:
McGraw Hill Education